WEBULL
WebtradeDownload

Is Slower da Vinci Placements Refocusing Intuitive Surgical’s (ISRG) Investment Case On Utilization Economics?

Simply Wall St · 1d ago
  • Intuitive Surgical recently reported that growth in new placements of its da Vinci surgical robots has cooled as competition intensifies and the robotics market evolves, shifting more of its business toward supporting the existing installed base.
  • This development highlights how Intuitive’s revenue is increasingly anchored by its annuity-like parts and services for in-use systems, underscoring the importance of utilization over new system sales.
  • We’ll now examine how this shift toward parts and service-driven revenue growth influences Intuitive Surgical’s investment narrative and long-term outlook.

Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

Intuitive Surgical Investment Narrative Recap

To own Intuitive Surgical, you need to believe that robotic-assisted procedures remain central to minimally invasive surgery and that utilization of its installed da Vinci base can support attractive recurring revenue. The recent slowdown in new system placements, as competition heats up, speaks directly to the biggest near term risk: pressure on system growth and pricing. For now, the main catalyst still appears to be procedure volumes and instrument usage on existing systems, and the news does not materially change that focus.

In this context, Intuitive’s recent recall activity for several da Vinci instruments and drapes is especially relevant. With the business shifting toward parts and service-driven revenue, product quality and regulatory reliability become even more critical to protecting utilization and preserving high margin recurring sales. Any missteps here could compound competitive pressures just as hospitals scrutinize costs more closely and weigh alternative suppliers or third party consumables.

Yet beneath the headline risk of slower system placements, investors also need to be aware that...

Read the full narrative on Intuitive Surgical (it's free!)

Intuitive Surgical's narrative projects $15.4 billion revenue and $4.7 billion earnings by 2029. This requires 11.8% yearly revenue growth and about a $1.6 billion earnings increase from $3.1 billion today.

Uncover how Intuitive Surgical's forecasts yield a $478.01 fair value, a 30% upside to its current price.

Exploring Other Perspectives

ISRG 1-Year Stock Price Chart
ISRG 1-Year Stock Price Chart

Some of the most optimistic analysts were expecting revenue to reach about US$17.2 billion and earnings around US$4.9 billion by 2029, but this latest cooling in new da Vinci placements could challenge those upbeat assumptions on faster upgrades and margin expansion, reminding you that views on Intuitive’s future can differ widely and may need a fresh look after this news.

Explore 11 other fair value estimates on Intuitive Surgical - why the stock might be worth 12% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Intuitive Surgical research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • Our free Intuitive Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intuitive Surgical's overall financial health at a glance.

No Opportunity In Intuitive Surgical?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.